These findings add breast cancer to the list of cancers susceptible to Rlip deficiency, joining melanoma, lung cancer, prostate cancer, colon cancer, renal cell carcinoma, pancreatic cancer, and neuroblastoma [27,34,37,38,39,40,41,58,60]. Here, RALBP1 is linked to renal cell carcinoma.